問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberJ4G-MC-JZVD
Not yet recruiting

2025-12-01 - 2033-05-05

Phase III

Recruiting5

ICD-10C67.9

Malignant neoplasm of bladder, unspecified

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9188.9

Malignant neoplasm of bladder, part unspecified

  • Trial Applicant

    ELI LILLY AND COMPANY(TAIWAN), INC.

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/03/01

Investigators and Locations

Principal Investigator 康乃文 Division of Hematology & Oncology

Co-Principal Investigator

Principal Investigator Wen-Jeng Wu Division of Urology

Co-Principal Investigator

Principal Investigator 陳彥勳 Division of Hematology & Oncology

Co-Principal Investigator

Principal Investigator Yu-Chieh Tsai Division of Hematology & Oncology

Co-Principal Investigator

Principal Investigator Ying-Chun Shen Division of Hematology & Oncology

Co-Principal Investigator

Principal Investigator Wen-Pin Su Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Jian-Ri Li Division of Urology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Yu-Li Su Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Yi-Hsiu Huang Division of Urology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chao-Hsiang Chang Division of Urology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    19-60 participants

  • Global

    450 participants